Comparative Pharmacology
Head-to-head clinical analysis: CEFADROXIL versus VELOSEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADROXIL versus VELOSEF.
CEFADROXIL vs VELOSEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefadroxil is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g orally once daily or divided into two doses every 12 hours.
250-500 mg orally every 6 hours or 1-2 g intramuscularly/intravenously every 6-12 hours for moderate to severe infections.
None Documented
None Documented
Terminal elimination half-life 1.1-1.5 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Clinical Note
moderateCefadroxil + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefadroxil."
Clinical Note
moderateCefadroxil + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefadroxil."
Clinical Note
moderateWarfarin + Cefadroxil
"Warfarin may increase the anticoagulant activities of Cefadroxil."
Clinical Note
moderatePhenprocoumon + Cefadroxil
1-2 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<5%).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); small biliary/fecal (5-10%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefadroxil."